Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HERCULES: Neoadjuvant Trastuzumab Deruxtecan in Stage II-III HER2-Amplified/Mutated NSCLC
NCT07428044Phase 2Withdrawn
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Feb 2026
- Primary completion
- Feb 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of trastuzumab deruxtecan in non-small cell lung cancer (NSCLC), sponsored by Memorial Sloan Kettering Cancer Center. Planned start Feb 2026; status: withdrawn.
02
Drugs
trastuzumab deruxtecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07428044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07428044.